Although more patients are receiving the TCIQ or the M780 system, it is important to note that even in developed nations most patients still use multiple daily insulin injections for insulin delivery.29 Furthermore, in a global perspective, most persons living with type 1 diabetes do not have access to CGM systems, which has been proven to reduce glucose levels in conjunction with MDI.30 Hence, an overall major challenge will be to make modern diabetes treatments more available for persons living with type 1 diabetes. The gene discussed is INS; the disease is type 1 diabetes mellitus.